Studying the Effectiveness of Ribavirin® in the Experimental Form of Severe Acute Respiratory Syndrome
https://doi.org/10.37489/0235-2990-2020-65-1-2-21-26
Abstract
The effectiveness of Ribavirin® was evaluated by the certainty of disease severity reduction and the coefficient of therapeutic action of drugs at the peak of the pathological process calculated by the following indicators: accumulation of the virus in the lungs, lung damage degree reduction, reduction observed in the severity of changes in the quantitative and qualitative characteristics of white blood, as well as the severity of changes in biochemical blood parameters. Ribavirin® is most effective when used according to the emergency prevention regimen at a dose of 20 mg/kg (therapeutic action coefficient — 70%); at a dose of 40 mg/kg according to the therapeutic and prophylactic regimen (therapeutic action coefficient — 60%). Increasing the dose of Ribavirin® did not contribute to the therapeutic effectiveness of the drug.
About the Authors
S. Ya. LoginovaRussian Federation
Sergiev Posad
V. N. Shchukina
Russian Federation
Sergiev Posad
S. V. Borisevich
Russian Federation
Sergiev Posad
R. A. Hamitov
Russian Federation
Moscow
V. A. Maksimov
Russian Federation
Sergiev Posad
References
1. Booth C.M., Matukas L.M., Tomlinson G.A. et al. Clinical features and short-term outcomes of 144 patients with SARS in the Greater Toronto Area. JAMA 2003; 289 (21): 2801–2809.
2. Tsang K.W., Ho P.L., Oi G.C. et al. Cluster of cases of Severe Acute Respiratory Syndrome in Hong Kong. New Engl Med 2003; 348 (20): 1977–1985.
3. Liu Z.Y., Li T.S., Wang Z. et al. Clinical features and therapy of 106 cases of severe acute respiratory syndrome. Zhonghua Nei Ke Za Zhi 2003; 42: 373–377.
4. Hensley L., Fritz E., Jahrling P. et al. Interferon-b 1a and SARS coronavirus replication. Emerg Infect Dis 2004; 10 (2): 317–319.
5. Koren G., King S., Knowles S., Phillips E. Ribavirin in treatment of SARS: A new Trick for an old drug? Can Med Ass J 2003; 168 (10): 1231.
6. Pak C., Lam C., Li A. et al. Inflammatory cytokine profile in children with severe acute respiratory syndrome. Pediatrics 2004; 113 (1): 7–14.
7. Tan E.L.C., Ooi E.E., Tan H.C. et al. Inhibition of SARS Coronovirus infection in vitro with clinical approved antiviral drugs. Emerg Infect Dis [serial online] 2004 Apr [cited 2004 February 24]. Available from: URL: http://www.cdc.gov/ncidod/EID/vol10no4/03-0458.htm
8. Zhao Z., Zhang F., Xu M. et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR Chine. J Med Microbiol 2003; 52: 715–20.
9. Zhaori G. Antiviral treatment of SARS: Can we draw any conclusions? CMAJ 2003; 169: 11.
10. Loginova S.Ja, Faldina V.N, Borisevich S.V. i dr. Izuchenie jeffektivnosti lekarstvennyh preparatov v otnoshenii virusa tjazhelogo ostrogo respiratornogo sindroma in vitro. Materialu konferentsii., posvjashhennoj 70-letiju Protivochumnogo centra «Protivochumnye uchrezhdenija Rossii i ih rol' v obespechenii jepidemiologicheskogo blagopoluchija naselenija strany». Moskva, 2004; 213. [in Russian]
11. Loginova S.Ja, Stepanova V.N, Borisevich S.V. i dr. Protivovirusnaja jeffektivnost' induktorov interferona i ribavirina v otnoshenii jeksperimental'noj formy tjazhelogo ostrogo respiratornogo sindroma. Tezisy dokladov «Hll Rossijskij nacional'nyj kongress «Chelovek i lekarstvo», posvjashhennyj 60-letiju pobedy v Velikoj otechestvennoj vojne 1941–1945 gg. 18–22 aprelja 2005g., Moskva. Moskva, 2005; 171. [in Russian]
12. Zhumatov K.H., Kydyrmanov A.I. Blizhnevostochnyj respiratornyj sindrom (MERS-Middle East Respiratory Syndrome): novaja koronavirusnaja infekcija cheloveka i zhivotnyh. Biotehnologija. Teorija i praktika 2015; 3: 4–10. [in Russian]
13. Syromjatnikova S.I., Markov V.I., Maksimov V.A., Stepanov N.N., Borisevich S.V., Merkulov V.A., Vasil'ev N.T., Onishhenko G.G., Piscov M.N. Shtamm SoD virusa tjazhelogo ostrogo respiratornogo sindroma roda Coronavirus, prednaznachennyj dlja razrabotki sredstv i metodov biologicheskoj zashhity. Patent RF № 2263144, 27.10.2005. [in Russian]
14. Rukovodstvo po provedeniju doklinicheskih issledovanij lekarstvennyh sredstv. Chast' 2. M., Minzdrav RF, 2013. [in Russian]
15. Borisevich S.V., Loginova S.Ja., Hamitov R.A., Maksimov V.A., Faldina V.N., Syromjatnikova S.I. Sposob modelirovanija tjazhelogo ostrogo respiratornogo sindroma u jeksperimental'nyh zhivotnyh. Patent RF №2280288, 20.07.2006. [in Russian]
16. Sinopalnikov A.I., Vorob`ev A.V. Tyazhely`j ostry`j respiratorny`j sindrom: novy`e fragmenty` golovolomki. Klin mikrobiol antimikrob ximioter 2004; 6 (№ 2): 108–123. [in Russian]
Review
For citations:
Loginova S.Ya., Shchukina V.N., Borisevich S.V., Hamitov R.A., Maksimov V.A. Studying the Effectiveness of Ribavirin® in the Experimental Form of Severe Acute Respiratory Syndrome. Antibiot Khimioter = Antibiotics and Chemotherapy. 2020;65(1-2):21-26. (In Russ.) https://doi.org/10.37489/0235-2990-2020-65-1-2-21-26